mAbs, 1942-0862

Journal

Related Publications
  1. (89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

    Pool, M., Kol, A., de Jong, S., de Vries, E. G. E., Lub-de Hooge, M. N. & Terwisscha van Scheltinga, A. G. T., 2017, In : mAbs. 9, p. 1370-1378 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

    Wiersma, V. R., de Bruyn, M., Shi, C., Gooden, M. J. M., Wouters, M. C. A., Samplonius, D. F., Hendriks, D., Nijman, H. W., Wei, Y., Zhou, J., Helfrich, W. & Bremer, E., 2015, In : mAbs. 7, 2, p. 321-330 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody Zr-89-RG7116

    Terwisscha Van Scheltinga, A. G. T., Lub-de Hooge, M. N., Abiraj, K., Schroder, C. P., Pot, L., Bossenmaier, B., Thomas, M., Holzlwimmer, G., Friess, T., Kosterink, J. G. W. & de Vries, L., 2014, In : mAbs. 6, 4, p. 1051-1058 8 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (3) »

ID: 14354524